Share This Article:

Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

Abstract Full-Text HTML XML Download Download as PDF (Size:311KB) PP. 132-135
DOI: 10.4236/jdm.2016.62013    2,094 Downloads   2,503 Views   Citations
Author(s)    Leave a comment

ABSTRACT

It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.

KEYWORDS

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Kabadi, U. (2016) Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!. Journal of Diabetes Mellitus, 6, 132-135. doi: 10.4236/jdm.2016.62013.

References

[1] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O.E., Woerle, H.J., Broedl, U.C. and Inzucchi, S.E., EMPA-REG Outcome Investigators (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128.
[2] UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853.
http://dx.doi.org/10.1016/S0140-6736(98)07019-6
[3] UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865.
http://dx.doi.org/10.1016/S0140-6736(98)07037-8
[4] Kabadi, U.M. (2002) United Kingdom Prospective Diabetes Study: A Different Perspective. Endocrine Practice, 8, 61-64.
http://dx.doi.org/10.4158/EP.8.1.61
[5] Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. and Neil, H.A. (2008) 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. The New England Journal of Medicine, 359, 1577-1589.
http://dx.doi.org/10.1056/NEJMoa0806470
[6] Seaquist, E.R., Miller, M.E., Bonds, D.E., Feinglos, M., Goff Jr., D.C., Peterson, K. and Senior, P., ACCORD Investigators (2012) The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD Study. Diabetes Care, 35, 409-414.
http://dx.doi.org/10.2337/dc11-0996
[7] Hanefeld, M., Duetting, E. and Bramlage, P. (2013) Cardiac Implications of Hypoglycaemia in Patients with Diabetes: A Systematic Review. Cardiovascular Diabetology, 21, 135.
[8] Tsujimoto, T., Yamamoto-Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M. and Noda, M. (2014) Vital Signs, QT Prolongation, and Newly Diagnosed Cardiovascular Disease during Severe Hypoglycemia in Type 1 and Type 2 Diabetic Patients. Diabetes Care, 37, 217-221.
http://dx.doi.org/10.2337/dc13-0701
[9] Chow, E., Bernjak, A., Williams, S., Fawdry, R.A., Hibbert, S., Freeman, J., Sheridan, P.J. and Heller, S.R. (2014) Risk of Cardiac Arrhythmias during Hypoglycemia in Patients with Type 2 Diabetes and Cardiovascular Risk. Diabetes, 63, 1738-1747.
http://dx.doi.org/10.2337/db13-0468
[10] Khunti, K., Davies, M., Majeed, A., Thorsted, B.L., Wolden, M.L. and Paul, S.K. (2015) Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People with Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 38, 316-322.
http://dx.doi.org/10.2337/dc14-0920
[11] Pistrosch, F. and Hanefeld, M. (2015) Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies. Current Diabetes Reports, 15, 117.
http://dx.doi.org/10.1007/s11892-015-0678-2
[12] Elwen, F.R., Huskinson, A., Clapham, L., Bottomley, M.J., Heller, S.R., James, C., Abbas, A., Baxter, P. and Ajjan, R.A. (2015) An Observational Study of Patient Characteristics and Mortality Following Hypoglycemia in the Community. BMJ Open Diabetes Research & Care, 3, Article ID: e000094.
[13] India Diabetes Management Algorithm Proposal Group (2016) A Proposed India-Specific Algorithm for Management of Type 2 Diabetes. Diabetes Technology and Therapeutics, 18, 1-5.
[14] Kabadi, U.M. (2015) Major Pathophysiologic Factor in Prediabetes and Type 2 Diabetes Mellitus: Decreased Insulin Secretion in Lean and Insulin Resistance in Obese subjects. Abstract No. 2016, Endocrine Society Annual Meeting.
[15] Naci, H., Basu, S. and Yudkin, J.S. (2015) Preventing Cardiovascular Events with Empagliflozin: At What Cost? The Lancet Diabetes & Endocrinology, 3, 931.
http://dx.doi.org/10.1016/S2213-8587(15)00439-8
[16] US Food and Drug Administration (2015) Drug Safety Communication: FDA Warns That SGLT2 Inhibitors for Diabetes May Result a Serious Condition of Too Much Acid in Blood. 15 May 2015.
http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf
[17] FDA Drug Safety Communication (2015) FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections. Posted 12 April 2015.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.